Cagent Vascular raises $41m for dual-modality IVL platform advancement

Cagent Vascular raised $41 million in funding to advance its Serranator SONIC intravascular lithotripsy (IVL) system. The capital will support completion of a pivotal clinical trial and commercial readiness for the dual-modality platform, which combines sonic and mechanical energy to treat calcified lesions in coronary and peripheral vessels.